TD Asset Management Inc Increases Holdings in Vera Therapeutics, Inc. $VERA

TD Asset Management Inc raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 54.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 325,564 shares of the company’s stock after buying an additional 115,090 shares during the quarter. TD Asset Management Inc’s holdings in Vera Therapeutics were worth $16,487,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the last quarter. Optimize Financial Inc grew its position in shares of Vera Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after acquiring an additional 256 shares during the period. Intech Investment Management LLC grew its position in shares of Vera Therapeutics by 2.4% during the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after acquiring an additional 424 shares during the period. Invesco Ltd. grew its position in shares of Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after acquiring an additional 550 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vera Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after acquiring an additional 639 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the completion of the sale, the chief executive officer owned 216,744 shares in the company, valued at approximately $7,963,174.56. This represents a 7.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Trading Down 1.7%

Shares of VERA stock opened at $31.75 on Tuesday. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The firm has a fifty day moving average price of $37.54 and a 200-day moving average price of $41.35. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -5.73 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period last year, the firm posted ($0.81) earnings per share. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Jefferies Financial Group reissued a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research report on Wednesday, March 11th. Finally, William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $78.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.